International Medical Journal, Vol. 20., Iss. 2, 2014, P. 33−37.
APPLICATION OF A NEW DRUG INFLUENCING ENDOCANNABINOID SYSTEM IN TREATMENT OF COMORBID GASTROENTEROLOGICAL PATHOLOGY
Kharkiv National Medical University
L.T. Malaya National Institute of Therapy NAMS of Ukraine, Kharkiv
The problem of increased body weight and obesity, manifesting by generalization of gastroenterological pathology, in particular gastroesophageal reflux disease and nonalcoholic fatty liver disease, has became noninfection pandemic recently. Main factor causing obesity is energy balance disorder, therefore reduction of excessive body mass, correction of nutrition behavior, hypocaloric diet, individual exercise programs are necessary. A new molecular target (a system of endocannabioids) playing an important role in energy balance regulation was revealed when working out the drugs for excessive weight correction. The drug influencing this target is Distressa, the efficacy and sefety of which was investigated in patients with comorbid gastroenterological pathology. Administration of the drug was accompanied by appetite reduction, quick saturation but did not inhibited the central nervous system. After the three−month course of therapy with Distressa the patients demonstrated positive dynamics of the main symptoms and signs of gastroesophageal reflux disease and nonalcoholic fatty liver disease. The endocannoid dependent receptors CB1 in the composition of Dietressa drug stabilized nutritional behavior of the patients and reduced their body weight.
Key words: nonalcoholic fatty liver disease, gastroesophageal reflux disease, obesity, treatment, Dietressa.